By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Prism Pharmaceuticals, Inc. 

Danbury  Connecticut    U.S.A.
Phone: n/a Fax:



Company News
Baxter International, Inc. (BAX) to Acquire Prism Pharmaceuticals, Inc. for $338 Million 4/19/2011 7:43:35 AM
Prism Pharmaceuticals, Inc. Receives FDA Approval of Ready-to-Use NEXTERONE(R) (amiodarone HCl) Premixed Injection 11/18/2010 7:11:41 AM
CyDex Pharmaceuticals Obtains Full Development and Commercialization Rights to Novel Captisol-Enabled(R) Intravenous Formulation of Clopidogrel; Terminating Agreement with Prism Pharmaceuticals, Inc. 10/12/2010 7:37:22 AM
Prism Pharmaceuticals, Inc.'s Study of Injectable Clopidogrel Accepted for Presentation at the American College of Cardiology 2/9/2009 10:54:45 AM
Prism Pharmaceuticals, Inc. to Receive $10 Million Milestone Payment from Paul Capital Healthcare 1/8/2009 7:38:44 AM
CyDex Pharmaceuticals Announces CAPTISOL(R) Technology Used in Recently Approved Cosolvent-Free Formulation of Amiodarone IV 1/5/2009 9:41:18 AM
Prism Pharmaceuticals, Inc. Receives FDA Approval of NEXTERONE(R) for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia 1/5/2009 7:17:04 AM
Prism Pharmaceuticals, Inc. Appoints Maurits Geerlings Vice President of Business Development 10/3/2007 7:35:59 AM
Prism Pharmaceuticals, Inc. Raises $68 Million To Advance Acute Care Portfolio 9/18/2006 1:31:36 PM
Hollister-Stier Laboratories Contract Manufacturing Signs Agreement With Prism Pharmaceuticals, Inc. 4/4/2006 12:29:02 PM